• Title/Summary/Keyword: ADCC

Search Result 8, Processing Time 0.022 seconds

The Effect of Methamphetamine on the Pulmonary Metastasis of B16 Melanoma Cells (Methamphetamine이 B16 악성 흑색종 세포 전이에 미치는 영향)

  • 신전수;박현애;정승태;김필선;손경희;선우연;한형미
    • Biomolecules & Therapeutics
    • /
    • v.3 no.4
    • /
    • pp.273-278
    • /
    • 1995
  • The effect of methamphetamine on the pulmonary metastasis was investigated in C57BL/6 mice injected with Bl6 melanoma cells. Bl6 melanoma cells (2$\times$10$^{5}$ cells) were injected intravenously into 5~7 weeks old C57BL/6 mice. Mice were then treated intraperitoneally with methamphetamine either acutely (two times with one week interval) or subchronically (daily for 14 days). Degree of pulmonary metastasis was investigated and specific immunologic parameters such as natural killer cell cytotoxicity(NKCC), antibody-dependent cellular cytotoxicity(ADCC) and blastogenic responses of splenocytes were examined. Mice which had been subchronically treated with methamphetamine showed significant decreases in the number of pulmonary metastasis of Bl6 melanoma cells, NKCC and ADCC without a significant change in blastogenic responses. In the acutely-treated group, slight trends of decrease in the numbers of pulmonary metastasis, NKCC and ADCC were observed without statistical significances whereas there was a significant increase in blastogenic responses. The mechanism underlying the decrease in the degree of metastasis despite diminished NKCC and ADCC after methamphetamine treatment and the relationship between the degree of pulmonary metastasis and duration of methamphetamine treatment remain to be investigated.

  • PDF

MCM3 as a Novel Diagnostic Marker in Benign and Malignant Salivary Gland Tumors

  • Ashkavandi, Zohreh Jaafari;Najvani, Ali Dehghani;Tadbir, Azadeh Andishe;Pardis, Soheil;Ranjbar, Mohammad Ali;Ashraf, Mohammad Javad
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.14 no.6
    • /
    • pp.3479-3482
    • /
    • 2013
  • Background: Proliferation markers widely have been used to diagnose and determine the behaviour and prognosis of benign and malignant tumours. Minichromosome maintenance 3 (MCM3) is a novel proliferation marker. The aim of this study was to evaluate and compare MCM3 with Ki-67 in diagnosis of salivary gland tumours. Materials and Methods: In this retrospective study, immunohistochemical expression of MCM3 and Ki-67 was evaluated in 15 pleomorphic adenomas (PA), 17 mucoepidermoid carcinomas (MEC) and 18 adenoid cystic carcinomas (ADCC). Labeling indices (LIs) for the two markers were calculated and compared. Results: MCM3 and Ki-67 LIs were significantly higher in MEC and ADCC compared to PA. The LI of MCM3 was significantly higher than that of Ki-67 in MEC and PA. There was no significant difference between the two markers in ADCC. A cut-off point of 8% with 74.3% sensitivity and 93.3% specificity for MCM3 was obtained to discern between benign and malignant tumors. Conclusions: These results suggest that MCM3 might be a useful proliferation marker for differential diagnosis and recognition of clinical behavior of salivary gland tumors.

Performance Analysis of Volatility Models for Estimating Portfolio Value at Risk (포트폴리오 VaR 측정을 위한 변동성 모형의 성과분석)

  • Yeo, Sung Chil;Li, Zhaojing
    • The Korean Journal of Applied Statistics
    • /
    • v.28 no.3
    • /
    • pp.541-559
    • /
    • 2015
  • VaR is now widely used as an important tool to evaluate and manage financial risks. In particular, it is important to select an appropriate volatility model for the rate of return of financial assets. In this study, both univariate and multivariate models are considered to evaluate VaR of the portfolio composed of KOSPI, Hang-Seng, Nikkei indexes, and their performances are compared through back testing techniques. Overall, multivariate models are shown to be more appropriate than univariate models to estimate the portfolio VaR, in particular DCC and ADCC models are shown to be more superior than others.

Characteristics of Physical Setting of Adult Day Care Center for the Elderly with Dementia in the U.S.A. (치매노인을 위한 주간보호시설의 물리적 환경 특성에 관한 연구 - 미국의 사례를 중심으로 -)

  • 곽인숙
    • Journal of the Korean Home Economics Association
    • /
    • v.40 no.7
    • /
    • pp.193-210
    • /
    • 2002
  • The purpose of this study is to identify the characteristics of physical setting of adult day care as a place for the elders and adult and to develop an basic understanding of the architectural program and physical setting for adult day care for the cognitively-impaired in the U.S.A. The data was collected from 13 Adult Day Care Centers(ADCC) from 2001 to 2002 by interview and the documents about those facilities. Physical environment should be viewed as an element in the care of individuals with dementia, and that the principles used to plan and design environment should be consistent with the principles used in providing other aspects of care. The results of the study provided the information about the best condition of physical setting of ADCC for the elderly with dementia. Memory Loss Adult Day Center and St. Ann Center for Intergenerational Care have better architectural program than other facilities. It is the hope of this study to provide guideline for design and care professionals with a first draft of a "sense-making" template and to slow own the progression of the disease by the appropriate physical environment.

A Study on Photonic sensor Interface in SOPC platform (SOPC기반 광-센서 인터페이스에 관한 연구)

  • Son, Hong-Bum;Park, Seong-Mo
    • Proceedings of the IEEK Conference
    • /
    • 2005.11a
    • /
    • pp.971-974
    • /
    • 2005
  • In this paper, we describe photonic sensor interface in SOPC(System on a programmable chip) platform. This platform uses device that has ARM922T processor and APEX FPGA area on a chip. We use two development kits. The one is embedded kit that using Intel's Xscale device, the another is SOPC kit that using Altera's Excalibur device. We implement some device logic that DMAC, ADCC, etc. and application.

  • PDF

Plant-based production of therapeutic antibodies (식물기반 치료용 항체생산)

  • Kim, Young-Kwan;So, Yang-Kang;Park, Da-Young;Kim, Hyun-Soon;Jeon, Jae-Heung;Choo, Young-Kug;Ko, Ki-Sung
    • Journal of Plant Biotechnology
    • /
    • v.37 no.3
    • /
    • pp.262-268
    • /
    • 2010
  • Antibodies are powerful and versatile tools to play a critical role in the diagnosis and treatment of many diseases. Their application has been enhanced significantly with the advanced recombinant DNA and heterologonous expression technologies, allowing to produce immunotherapeutic proteins with improved biofunctional properties. However, with currently available technologies, mammalian cell-based therapeutic antibody production, as an alternative for production in humans and animals, is often not plentiful for passive immunotherapeutics in treatment of many diseases. Recently, plant expression systems for therapeutic antibodies have become well-established. Thus, plants have been considered to provide an attractive alternative production system for therapeutic antibodies, as plants have several advantages such as the lack of human pathogens, and low cost of upstream production and flexible scale-up of highly valuable recombinant glycoproteins. Recent advances in modification of posttranslational processing for human-like glycosylation in transgenic plants will make it possible that plant can become a suitable protein expression system over the animal cellbased current production system. This review will discuss recent advances in plant expression technology and issues for their application to therapeutic antibody production.

HOCl Oxidation-modified CT26 Cell Vaccine Inhibits Colon Tumor Growth in a Mouse Model

  • Zhou, Rui;Huang, Wen-Jun;Ma, Cong;Zhou, Yan;Yao, Yu-Qin;Wang, Yu-Xi;Gou, Lan-Tu;Yi, Chen;Yang, Jin-Liang
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.8
    • /
    • pp.4037-4043
    • /
    • 2012
  • Despite progress in elucidating mechanisms associated with colorectal cancer and improvement of treatment methods, it remains a frequent cause of death worldwide. New and more effective therapies are therefore urgently needed. Recent studies have shown that immunogenicity of whole ovarian tumor cells and subsequent T cell response were potentiated by oxidation modification with hypochlorous acid (HOCl) in vitro and ex vivo. These results prompted us to investigate the protective antitumor response with an HOCl treated CT26 colorectal cancer cell vaccine in an in vivo mouse model. Administration of HOCl modified vaccine triggered robust antitumor immunity to autologous tumor cells in mice and prolonged survival period significantly. In addition, increased necrosis and apoptosis were found in tumor tissue from the oxidation group. Interestingly, ELISPOT assays showed that specific T cell responses were not elicited in response to the immunizing cellular antigen, in contrast to raising sera antibody titer and antibody binding activity shown by ELISA assay and flow cytometry. Further evaluation of the mechanisms underlying HOCl modified vaccine mediated humoral immunity highlighted the role of antibody-dependent cell-mediated cytotoxicity. These results combined with previous studies suggest that HOCl oxidation modified whole cell vaccine has wide applicability as a cancer vaccine because it can target both T cell- and B cell-specific responses. It may thus represent a promising approach for the immunotherapy of colorectal cancer.

A Novel Anti-PD-L1 Antibody Exhibits Antitumor Effects on Multiple Myeloma in Murine Models via Antibody-Dependent Cellular Cytotoxicity

  • Ahn, Jae-Hee;Lee, Byung-Hyun;Kim, Seong-Eun;Kwon, Bo-Eun;Jeong, Hyunjin;Choi, Jong Rip;Kim, Min Jung;Park, Yong;Kim, Byung Soo;Kim, Dae Hee;Ko, Hyun-Jeong
    • Biomolecules & Therapeutics
    • /
    • v.29 no.2
    • /
    • pp.166-174
    • /
    • 2021
  • Multiple myeloma is a malignant cancer of plasma cells. Despite recent progress with immunomodulatory drugs and proteasome inhibitors, it remains an incurable disease that requires other strategies to overcome its recurrence and non-response. Based on the high expression levels of programmed death-ligand 1 (PD-L1) in human multiple myeloma isolated from bone marrow and the murine myeloma cell lines, NS-1 and MOPC-315, we propose PD-L1 molecule as a target of anti-multiple myeloma therapy. We developed a novel anti-PD-L1 antibody containing a murine immunoglobulin G subclass 2a (IgG2a) fragment crystallizable (Fc) domain that can induce antibody-dependent cellular cytotoxicity. The newly developed anti-PD-L1 antibody showed significant antitumor effects against multiple myeloma in mice subcutaneously, intraperitoneally, or intravenously inoculated with NS-1 and MOPC-315 cells. The anti-PD-L1 effects on multiple myeloma may be related to a decrease in the immunosuppressive myeloid-derived suppressor cells (MDSCs), but there were no changes in the splenic MDSCs after combined treatment with lenalidomide and the anti-PD-L1 antibody. Interestingly, the newly developed anti-PD-L1 antibody can induce antibody-dependent cellular cytotoxicity in the myeloma cells, which differs from the existing anti-PD-L1 antibodies. Collectively, we have developed a new anti-PD-L1 antibody that binds to mouse and human PD-L1 and demonstrated the antitumor effects of the antibody in several syngeneic murine myeloma models. Thus, PD-L1 is a promising target to treat multiple myeloma, and the novel anti-PD-L1 antibody may be an effective anti-myeloma drug via antibody-dependent cellular cytotoxicity effects.